We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Read MoreHide Full Article
Key Takeaways
Recursion uses its AI platform, RecursionOS, to simulate drug interactions and speed up discovery.
Partnerships with Bayer and Roche validate RXRX's model and provide recurring tech-licensing revenues.
RXRX faces growing competition from TechBio peers like RLAY and SDGR with similarly advanced platforms.
Recursion Pharmaceuticals (RXRX - Free Report) is redefining the traditional model of drug discovery by harnessing the power of artificial intelligence (AI) through its proprietary RecursionOS platform, developed in collaboration with NVIDIA Corporation. Instead of relying on time-consuming and costly research and development, RXRX uses AI to simulate how compounds interact with a virtual map of human biology, aiming to identify drug candidates with higher chances of clinical success. This method reduces costs, increases efficiency, and may enable faster, more affordable development of breakthrough therapies.
Beyond its pipeline, Recursion Pharmaceuticals’ AI platform has broad commercial potential. Partnerships with pharma giants like Bayer and Roche highlight industry validation and offer recurring revenue through technology licensing. Even when drug candidates fail in studies, the data collected feeds back into the AI system, making future predictions more accurate. This self-learning feature could significantly refine and enhance its AI models, improving accuracy and long-term outcomes.
RXRX Faces Competitive Pressure in the TechBio Industry
Recursion Pharmaceuticals operates in a competitive landscape, where it faces challenges from a range of companies across the pharmaceutical, biotechnology and technology sectors. As a hybrid company, it competes on multiple fronts, integrating advanced technologies into drug discovery and development while building a scalable scientific platform.
In the TechBio space, Relay Therapeutics (RLAY - Free Report) and Schrödinger (SDGR - Free Report) are emerging as strong competitors to Recursion Pharmaceuticals. RLAY uses its Dynamo platform to target challenging protein structures and is on track to advance its lead investigational candidate, RLY-2608, into a phase III study for metastatic breast cancer. An early-stage study evaluating the candidate for a second indication, vascular malformations, is also currently underway.
Meanwhile, SDGR relies on a unique physics-based computational platform to design novel molecules, with its lead asset SGR-1505 in an early-stage study for B-cell malignancies. Schrödinger is also evaluating two other candidates, SGR-2921 and SGR-3515, in separate phase I studies for leukemia and solid tumors. Both Relay Therapeutics and Schrödinger are steadily building robust pipelines through cutting-edge approaches.
Year to date, RXRX shares have plunged 24.1% compared with the industry’s 3.4% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
RXRX Stock Underperforms the Industry, Sector & the S&P 500
Image Source: Zacks Investment Research
Recursion Pharmaceuticals is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 2.23, which is less than 3.05 for the industry. The stock is trading significantly below its five-year mean of 3.63.
Image Source: Zacks Investment Research
(insert chart)
Loss estimates for 2025 have remained constant at $1.34 per share over the past 60 days. During the same time frame, RXRX’s 2026 loss per share estimates have narrowed from $1.20 to $1.08.
Image: Bigstock
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Key Takeaways
Recursion Pharmaceuticals (RXRX - Free Report) is redefining the traditional model of drug discovery by harnessing the power of artificial intelligence (AI) through its proprietary RecursionOS platform, developed in collaboration with NVIDIA Corporation. Instead of relying on time-consuming and costly research and development, RXRX uses AI to simulate how compounds interact with a virtual map of human biology, aiming to identify drug candidates with higher chances of clinical success. This method reduces costs, increases efficiency, and may enable faster, more affordable development of breakthrough therapies.
Beyond its pipeline, Recursion Pharmaceuticals’ AI platform has broad commercial potential. Partnerships with pharma giants like Bayer and Roche highlight industry validation and offer recurring revenue through technology licensing. Even when drug candidates fail in studies, the data collected feeds back into the AI system, making future predictions more accurate. This self-learning feature could significantly refine and enhance its AI models, improving accuracy and long-term outcomes.
RXRX Faces Competitive Pressure in the TechBio Industry
Recursion Pharmaceuticals operates in a competitive landscape, where it faces challenges from a range of companies across the pharmaceutical, biotechnology and technology sectors. As a hybrid company, it competes on multiple fronts, integrating advanced technologies into drug discovery and development while building a scalable scientific platform.
In the TechBio space, Relay Therapeutics (RLAY - Free Report) and Schrödinger (SDGR - Free Report) are emerging as strong competitors to Recursion Pharmaceuticals. RLAY uses its Dynamo platform to target challenging protein structures and is on track to advance its lead investigational candidate, RLY-2608, into a phase III study for metastatic breast cancer. An early-stage study evaluating the candidate for a second indication, vascular malformations, is also currently underway.
Meanwhile, SDGR relies on a unique physics-based computational platform to design novel molecules, with its lead asset SGR-1505 in an early-stage study for B-cell malignancies. Schrödinger is also evaluating two other candidates, SGR-2921 and SGR-3515, in separate phase I studies for leukemia and solid tumors. Both Relay Therapeutics and Schrödinger are steadily building robust pipelines through cutting-edge approaches.
RXRX’s Stock Price, Valuation & Estimate Movements
Year to date, RXRX shares have plunged 24.1% compared with the industry’s 3.4% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
RXRX Stock Underperforms the Industry, Sector & the S&P 500
Recursion Pharmaceuticals is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 2.23, which is less than 3.05 for the industry. The stock is trading significantly below its five-year mean of 3.63.
(insert chart)
Loss estimates for 2025 have remained constant at $1.34 per share over the past 60 days. During the same time frame, RXRX’s 2026 loss per share estimates have narrowed from $1.20 to $1.08.
RXRX Estimate Movement
Recursion Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.